Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,276
archived clinical trials in
Pancreatic Cancer

Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
USOR - TX Oncology Austin
mi
from
Austin, TX
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
USOR - TX Oncology Austin
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
USOR -TX Oncology Dallas
mi
from
Dallas, TX
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
USOR -TX Oncology Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
USOR - TX Oncology Tyler
mi
from
Tyler, TX
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
USOR - TX Oncology Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
USOR - VA Cancer Specialists
mi
from
Fairfax, VA
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
USOR - VA Cancer Specialists
mi
from
Fairfax, VA
Click here to add this to my saved trials
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
USOR - VA Oncology Associates
mi
from
Norfolk, VA
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
USOR - VA Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
USOR - Rocky Mountain Cancer Center
mi
from
Denver, CO
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
USOR - Rocky Mountain Cancer Center
mi
from
Denver, CO
Click here to add this to my saved trials
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
Horizon Oncology Research, Inc.
mi
from
Lafayette, IN
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
Horizon Oncology Research, Inc.
mi
from
Lafayette, IN
Click here to add this to my saved trials
Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer
A Phase I, Safety Trial of Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer
A Phase I, Safety Trial of Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
A Phase I Study Evaluating the Safety and Efficacy of TGR 1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics Trial Site
mi
from
Nashville, TN
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
A Phase I Study Evaluating the Safety and Efficacy of TGR 1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics Trial Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Cancer Center
mi
from
Scottsdale, AZ
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Cancer Center
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of California, Los Angeles (UCLA) Medical Center - Santa Monica Cancer Center
mi
from
Santa Monica, CA
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of California, Los Angeles (UCLA) Medical Center - Santa Monica Cancer Center
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Cancer Center - Jacksonville
mi
from
Jacksonville, FL
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Cancer Center - Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of South Alabama - Mobile
mi
from
Mobile, AL
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of South Alabama - Mobile
mi
from
Mobile, AL
Click here to add this to my saved trials
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of Colorado (CU) Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of Colorado (CU) Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Cancer Center - Rochester
mi
from
Rochester, MN
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Cancer Center - Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Holy Name Medical Center - Teaneck
mi
from
Teaneck, NJ
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Holy Name Medical Center - Teaneck
mi
from
Teaneck, NJ
Click here to add this to my saved trials
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of Oklahoma Health Sciences Center (OUHSC) Stephenson Cancer Center
mi
from
Oklahoma City, OK
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of Oklahoma Health Sciences Center (OUHSC) Stephenson Cancer Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Houston Methodist Cancer Center and Institute of Academic Medicine
mi
from
Houston, TX
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Houston Methodist Cancer Center and Institute of Academic Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Oncology Consultants - Houston
mi
from
Houston, TX
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Oncology Consultants - Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Joe Arrington Cancer Research and Treatment Center - Lubbock
mi
from
Lubbock, TX
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Joe Arrington Cancer Research and Treatment Center - Lubbock
mi
from
Lubbock, TX
Click here to add this to my saved trials
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
St. John of God Health Care - Subiaco
mi
from
Subiaco,
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
St. John of God Health Care - Subiaco
mi
from
Subiaco,
Click here to add this to my saved trials
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of South Alabama
mi
from
Mobile, AL
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of South Alabama
mi
from
Mobile, AL
Click here to add this to my saved trials
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Arizona Center for Cancer Care
mi
from
Avondale, AZ
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Arizona Center for Cancer Care
mi
from
Avondale, AZ
Click here to add this to my saved trials
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
US Oncology - Comprehensive Cancer Centers of Nevada (CCCN)
mi
from
Las Vegas, NV
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
US Oncology - Comprehensive Cancer Centers of Nevada (CCCN)
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Gettysburg Cancer Center
mi
from
Gettysburg, PA
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Gettysburg Cancer Center
mi
from
Gettysburg, PA
Click here to add this to my saved trials
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Medical Group of the Carolinas - Spartanburg Regional Health Services
mi
from
Spartanburg, SC
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Medical Group of the Carolinas - Spartanburg Regional Health Services
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma
Pilot Study of the Feasibility and Safety of a Personalized Peptide Vaccine in Patients With Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma
Pilot Study of the Feasibility and Safety of a Personalized Peptide Vaccine in Patients With Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
mi
from
Phoenix, AZ
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Vita Medical Associates P.C.
mi
from
Bethlehem, PA
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Vita Medical Associates P.C.
mi
from
Bethlehem, PA
Click here to add this to my saved trials
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Banner Health
mi
from
Gilbert, AZ
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Banner Health
mi
from
Gilbert, AZ
Click here to add this to my saved trials
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Atlantic Health System Morristown Medical Center
mi
from
Morristown, NJ
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Atlantic Health System Morristown Medical Center
mi
from
Morristown, NJ
Click here to add this to my saved trials
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated:  12/31/1969
The Beatson West of Scotland Cancer Centre
mi
from
Glasgow,
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated: 12/31/1969
The Beatson West of Scotland Cancer Centre
mi
from
Glasgow,
Click here to add this to my saved trials
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Sarcoma Oncology Research Center
mi
from
Santa Monica, CA
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Sarcoma Oncology Research Center
mi
from
Santa Monica, CA
Click here to add this to my saved trials
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Global Cancer Research Institute
mi
from
Gilroy, CA
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Global Cancer Research Institute
mi
from
Gilroy, CA
Click here to add this to my saved trials
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Epidural Analgesia Use in Pancreatic Resections
Epidural Analgesia Use in Pancreatic Resections
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Epidural Analgesia Use in Pancreatic Resections
Epidural Analgesia Use in Pancreatic Resections
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Ultrasound Monitoring of Abdominal Soft Tissue
Ultrasound System For Non-Invasive, Real-Time Monitoring of Abdominal Soft Tissue
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Ultrasound Monitoring of Abdominal Soft Tissue
Ultrasound System For Non-Invasive, Real-Time Monitoring of Abdominal Soft Tissue
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene
Phase II Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene
Phase II Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Phase I/II of Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Phase I/II of Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Phase I/II of Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Phase I/II of Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer
A Phase II Trial of Weekly Gemcitabine Hydrochloride and Bevacizumab in Combination With Abdominal Radiation Therapy in Patients With Localized Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer
A Phase II Trial of Weekly Gemcitabine Hydrochloride and Bevacizumab in Combination With Abdominal Radiation Therapy in Patients With Localized Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
Phase II Study of the Anti-Vascular Endothelial Growth Factor (α-VEGF) Monoclonal Antibody Bevacizumab in Combination With Fixed Dose Rate (FDR) Gemcitabine and Rapid-Fractionation Radiotherapy in the Pre-operative Treatment of Potentially- Resectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Centers
mi
from
Pittsburgh, PA
Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
Phase II Study of the Anti-Vascular Endothelial Growth Factor (α-VEGF) Monoclonal Antibody Bevacizumab in Combination With Fixed Dose Rate (FDR) Gemcitabine and Rapid-Fractionation Radiotherapy in the Pre-operative Treatment of Potentially- Resectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Centers
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Endoscopic Ultrasound Guided Fine Needle Biopsy (EUS-FNB-SC) Using a Novel Fork Needle
Pilot-Feasibility Trial of EUS Guided Pancreas Fine Needle Core Biopsy for Whole Exome Sequencing and Genomic Profiling
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
mi
from
Jacksonville, FL
Endoscopic Ultrasound Guided Fine Needle Biopsy (EUS-FNB-SC) Using a Novel Fork Needle
Pilot-Feasibility Trial of EUS Guided Pancreas Fine Needle Core Biopsy for Whole Exome Sequencing and Genomic Profiling
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials